German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP).
This German post-authorisation safety study (PASS; EUPAS13004) evaluated the real-world safety and clinical effectiveness of afamelanotide 16 mg (SCENESSE) in 200 patients with erythropoietic protoporphyria (EPP), a rare inherited disorder causing severe acute phototoxicity upon light exposure. As an ongoing observational study linked to the European EPP Disease Registry, it collected treatment-emergent adverse events as the primary safety variable and used the validated EPP-Quality of Life (EPP-QoL) tool alongside treatment continuity as effectiveness measures. The study found that afamelanotide's real-world safety and benefit-risk profile was consistent with that observed in prior clinical trials. Patients reported a statistically significant improvement in quality of life compared to baseline (p-value not fully quoted in the abstract). High treatment continuity was also noted, suggesting ongoing clinical benefit. Key limitations include the absence of an untreated comparator group within this cohort, the observational (non-randomised) design, and potential for selection bias inherent in registry-based studies. The authors concluded that afamelanotide demonstrated a positive safety profile and was associated with improved quality of life in EPP patients under real-world conditions.
Why this grade: While conducted in humans with a meaningful sample size (n=200), the non-randomised, single-arm observational registry design with no untreated comparator group limits causal inference and elevates risk of bias.
Background Afamelanotide 16 mg (SCENESSE) is the first approved treatment for erythropoietic protoporphyria (EPP). EPP is a rare autosomal recessive inherited disorder of the haem biosynthesis pathway, where patients experience severe and debilitating acute phototoxicity. It affects at least one in 140,000 of the European population. A postauthorisation safety study (PASS) and a disease registry were imposed as conditions of the European marketing authorisation. Objectives Evaluate the short- and long-term safety and clinical effectiveness of afamelanotide 16 mg in EPP patients enrolled in the PASS in Germany. Methods The PASS (EUPAS13004) is an ongoing observational study collecting safety and effectiveness variables from treated and untreated EPP patients in the European EPP Disease Registry. Patients (n = 200, none untreated) received afamelanotide according to the summary of product characteristics. Treatment-emergent adverse events were collected as safety variables. Clinical effectiveness was assessed with the EPP-QoL tool and through treatment continuity. Results The short- and long-term safety and benefit-risk profile of afamelanotide under real-world conditions is consistent with the positive safety profile seen in clinical trials. EPP patients reported a significant increase in QoL compared with baseline values (p Conclusions Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients. The study shows a positive safety profile of afamelanotide, with the treatment providing an ongoing clinical benefit.
Educational summary of published research — not medical advice. License: cc by-nc-nd. Full text is shown only where licensing permits.